Lanreotide acetate and Zide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lanreotide acetate (lanreotide acetate) and Zide (hydrochlorothiazide). Common drug interactions include gastric ulcer among females and injection site pain among males.

The phase IV clinical study analyzes what interactions people have when they take Lanreotide acetate and Zide. It is created by eHealthMe based on reports of 59 people who take the same drugs from the FDA, and is updated regularly.

What is Lanreotide acetate?

Lanreotide acetate has active ingredients of lanreotide acetate. eHealthMe is studying from 2,168 Lanreotide acetate users. Check the latest studies of Lanreotide acetate.

What is Zide?

Zide has active ingredients of hydrochlorothiazide. It is often used in high blood pressure. eHealthMe is studying from 183,246 Zide users. Check the latest studies of Zide.

On Jul, 15, 2026

59 people who take Lanreotide acetate and Zide together, and have interactions are studied.

Lanreotide acetate and Zide drug interactions.

What are the common drug interactions of Lanreotide Acetate and Zide, by gender? *:

female:

Gastric ulcer (stomach ulcer)
Gastritis (inflammation of stomach)
Injection site mass
Neoplasm malignant (cancer tumour)
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Pain of skin
Stress
Fall
Fatigue (feeling of tiredness)
Flatulence (flatus expelled through the anus)

male:

Injection site pain
Respiratory rate increased (excess breathing rate/min)
Dyspnoea at rest (difficult or laboured breathing during rest)
Faeces pale
Injection site haemorrhage (bleeding from injection site)
International normalised ratio increased
Muscular weakness (muscle weakness)
Nephrolithiasis (calculi in the kidneys)
Pain in extremity
Rash

What are the common drug interactions of Lanreotide Acetate and Zide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Hypoglycaemia (deficiency of glucose in the bloodstream)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Arthralgia (joint pain)
Constipation
Headache (pain in head)
Hyperhidrosis (abnormally increased sweating)
Neoplasm (tumour)
Feeling cold
Loss of consciousness
Overdose
Peripheral coldness
Syncope (loss of consciousness with an inability to maintain postural tone)

50-59:

n/a

60+:

Injection site pain
Diarrhoea
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Cough
Arthralgia (joint pain)
Headache (pain in head)
Injection site haemorrhage (bleeding from injection site)
Pain in extremity
Blood glucose increased
Injection site mass

What are the existing conditions these people have? *

Neuroendocrine Tumor: 17 people, 28.81%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 12 people, 20.34%
Carcinoid Syndrome (syndrome includes flushing and diarrhoea, and, less frequently, heart failure and bronchoconstriction): 11 people, 18.64%
Nausea (feeling of having an urge to vomit): 9 people, 15.25%
Pain: 7 people, 11.86%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 7 people, 11.86%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 6.78%
Carcinoid Tumor: 3 people, 5.08%

* Approximation only. Some reports may have incomplete information.

Do you take Lanreotide acetate and Zide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously